Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Veracyte Inc (NQ: VCYT ) 29.77 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Sep 5, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Veracyte Inc < Previous 1 2 3 4 5 6 Next > New Data Presented at the 2023 ATA Annual Meeting Demonstrate that Veracyte’s Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer September 28, 2023 From Veracyte, Inc. Via Business Wire Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023 September 28, 2023 From Veracyte, Inc. Via Business Wire Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer September 27, 2023 From Veracyte, Inc. Via Business Wire Veracyte Announces Novel Afirma-Based Findings that Advance Molecular Understanding of Thyroid Cancer to Be Presented at the 2023 ATA Annual Meeting September 21, 2023 From Veracyte, Inc. Via Business Wire Veracyte Names Marie-Claire Taine, Ph.D., as General Manager of Its IVD Business Unit To Advance Global Expansion of the Company’s Tests September 07, 2023 From Veracyte, Inc. Via Business Wire Veracyte and Gustave Roussy Announce Collaboration to Help Biopharmaceutical Companies Accelerate Development of Novel Cancer Therapies September 06, 2023 From Veracyte, Inc. Via Business Wire Veracyte to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference August 29, 2023 From Veracyte, Inc. Via Business Wire Veracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer August 22, 2023 From Veracyte, Inc. Via Business Wire Veracyte Earns Top Workplace Awards in the San Francisco Bay Area and San Diego August 15, 2023 From Veracyte, Inc. Via Business Wire Veracyte Announces Second Quarter 2023 Financial Results August 08, 2023 From Veracyte, Inc. Via Business Wire Study Published in JNCI Cancer Spectrum Demonstrates Real-World Utility of Veracyte’s Decipher Prostate Genomic Classifier in Prostate Cancer Treatment August 01, 2023 From Veracyte, Inc. Via Business Wire Veracyte to Release Second Quarter 2023 Financial Results on August 8, 2023 July 19, 2023 From Veracyte, Inc. Via Business Wire New Data Suggest Veracyte’s Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and Cancer June 20, 2023 From Veracyte, Inc. Via Business Wire Veracyte Announces Afirma-Focused Abstracts to Be Presented at ENDO 2023 June 12, 2023 From Veracyte, Inc. Via Business Wire Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June May 31, 2023 EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:JAZZ),(NASDAQ:GERN),(NASDAQ:INAB),(NASDAQ:VCYT) EQNX::TICKER_END Via FinancialNewsMedia Exposures Product Safety New Data To Be Shared at 2023 ASCO Demonstrate Power of Veracyte’s Decipher GRID To Help Advance Molecular Understanding of Prostate Cancer May 25, 2023 From Veracyte, Inc. Via Business Wire New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer May 24, 2023 From Veracyte, Inc. Via Business Wire Veracyte to Participate in Upcoming Investor Conferences May 23, 2023 From Veracyte, Inc. Via Business Wire Veracyte Announces that New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer May 12, 2023 From Veracyte, Inc. Via Business Wire A New Groundbreaking Tool to Detect Colon Cancer Earlier May 10, 2023 A novel blood test for detecting colon cancer, the third most lethal type of cancer in the US, has been created. The Colorectal Cancer Screening Blood Test can identify cancer at early stages. This... Via PressReach Exposures Product Safety Veracyte Announces First Quarter 2023 Financial Results May 04, 2023 From Veracyte, Inc. Via Business Wire New Data Being Presented at AACE 2023 Help Elucidate Cancer Risk of TERT Promoter Gene Mutations in Patients with Indeterminate Thyroid Nodules May 04, 2023 From Veracyte, Inc. Via Business Wire New Data Published In Cancer Suggest Decipher GRID-Derived Gene Expression Signature Could Enable More Personalized Treatment for Prostate Cancer Patients May 03, 2023 From Veracyte, Inc. Via Business Wire New Artificial Intelligence Tool Can Diagnose Colon Cancer May 03, 2023 A new artificial intelligence (AI) model developed by Harvard Medical School and Taiwan’s National Cheng Kung University could provide much-needed clarity to clinicians presenting prognoses and... Via PressReach Topics Artificial Intelligence Death Exposures Artificial Intelligence Death Product Safety Veracyte Announces Release of Inaugural ESG Report May 03, 2023 From Veracyte, Inc. Via Business Wire Data Published in "The Red Journal” Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier To Help Guide Therapy in Men with Intermediate-Risk Prostate Cancer May 02, 2023 From Veracyte, Inc. Via Business Wire Three Abstracts Focusing on the Clinical Utility of Veracyte’s Genomic Tests in ILD and Lung Cancer To Be Presented at ATS 2023 International Conference May 01, 2023 From Veracyte, Inc. Via Business Wire Findings From Two Large-Scale, Real-World Data Sets Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier April 29, 2023 From Veracyte, Inc. Via Business Wire Veracyte Announces Five Abstracts Providing Molecular Insights Into Prostate and Other Cancers To Be Presented at the 2023 ASCO Annual Meeting April 27, 2023 From Veracyte, Inc. Via Business Wire New Data Reinforce Ability of Veracyte’s Decipher Prostate Genomic Classifier To Help Identify Prostate Cancer Patients Who Would Benefit from Treatment Intensification April 17, 2023 From Veracyte, Inc. Via Business Wire < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.